Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF.

Boeters DM, Nieuwenhuis WP, Verheul MK, Newsum EC, Reijnierse M, Toes RE, Trouw LA, van der Helm-van Mil AH.

Arthritis Res Ther. 2016 Aug 2;18:179. doi: 10.1186/s13075-016-1076-0.

2.

Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis, First-Degree Relatives and Controls: Comparison to Anti-Citrullinated Protein Antibodies- Reply to letter to the editor from Hutchinson and colleagues.

Hitchon CA, Koppejan H, Trouw LA, Huizinga TJ, Toes RE, El-Gabalawy HS.

Arthritis Rheumatol. 2016 Aug 2. doi: 10.1002/art.39831. [Epub ahead of print]

PMID:
27483087
3.

Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus.

Magro-Checa C, Schaarenburg RA, Beaart HJ, Huizinga TW, Steup-Beekman GM, Trouw LA.

Lupus. 2016 Jul;25(8):878-88. doi: 10.1177/0961203316643170.

PMID:
27252265
4.

Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation.

Verheul MK, van Erp SJ, van der Woude D, Levarht EW, Mallat MJ, Verspaget HW, Stolk J, Toes RE, van der Meulen-de Jong AE, Hiemstra PS, van Kooten C, Trouw LA.

Ann Rheum Dis. 2016 Aug;75(8):1575-6. doi: 10.1136/annrheumdis-2016-209248. Epub 2016 Apr 29. No abstract available.

PMID:
27130909
5.

The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.

Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE, Huizinga TW, Svensson B, Trouw LA, van der Helm-van Mil AH.

Ann Rheum Dis. 2016 Apr 26. pii: annrheumdis-2015-208870. doi: 10.1136/annrheumdis-2015-208870. [Epub ahead of print]

PMID:
27117699
6.

Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.

Koppejan H, Trouw LA, Sokolove J, Lahey LJ, Huizinga TJ, Smolik IA, Robinson DB, El-Gabalawy HS, Toes RE, Hitchon CA.

Arthritis Rheumatol. 2016 Sep;68(9):2090-8. doi: 10.1002/art.39664.

PMID:
26946484
7.

Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.

Akdemir G, Verheul MK, Heimans L, Wevers-de Boer KV, Goekoop-Ruiterman YP, van Oosterhout M, Harbers JB, Bijkerk C, Steup-Beekman GM, Lard LR, Huizinga TW, Trouw LA, Allaart CF.

RMD Open. 2016 Feb 15;2(1):e000172. doi: 10.1136/rmdopen-2015-000172. eCollection 2016.

8.

Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis.

Brink M, Hansson M, Mathsson-Alm L, Wijayatunga P, Verheul MK, Trouw LA, Holmdahl R, Rönnelid J, Klareskog L, Rantapää-Dahlqvist S.

Arthritis Res Ther. 2016 Feb 9;18:43. doi: 10.1186/s13075-016-0940-2.

9.

Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.

Ajeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies JA, Hafström I, Svensson B, Huizinga TW, Trouw LA, Verstappen SM, van der Helm-van Mil AH.

Ann Rheum Dis. 2016 Jan 12. pii: annrheumdis-2015-208579. doi: 10.1136/annrheumdis-2015-208579. [Epub ahead of print]

PMID:
26757747
10.

The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis.

Shi J, van Steenbergen HW, van Nies JA, Levarht EW, Huizinga TW, van der Helm-van Mil AH, Toes RE, Trouw LA.

Arthritis Res Ther. 2015 Nov 24;17:339. doi: 10.1186/s13075-015-0860-6.

11.

Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register.

Humphreys JH, Verheul MK, Barton A, MacGregor AJ, Lunt M, Toes RE, Symmons DP, Trouw LA, Verstappen SM.

Ann Rheum Dis. 2016 Jun;75(6):1139-44. doi: 10.1136/annrheumdis-2015-207326. Epub 2015 Oct 6.

12.

An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.

van Heemst J, Trouw LA, Nogueira L, van Steenbergen HW, van der Helm-van Mil AH, Allaart CF, Serre G, Holmdahl R, Huizinga TW, Toes RE, van der Woude D.

Arthritis Res Ther. 2015 Oct 5;17:276. doi: 10.1186/s13075-015-0786-z.

13.

Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis.

Foltyn Zadura A, Memon AA, Stojanovich L, Perricone C, Conti F, Valesini G, Bogdanovic G, Hillarp A, Shoenfeld Y, Sundquist J, Leffler J, Svensson PJ, Trouw LA, Blom AM.

J Rheumatol. 2015 Oct;42(10):1786-93. doi: 10.3899/jrheum.150185. Epub 2015 Aug 15.

PMID:
26276971
14.

Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis.

Habets KL, Trouw LA, Levarht EW, Korporaal SJ, Habets PA, de Groot P, Huizinga TW, Toes RE.

Arthritis Res Ther. 2015 Aug 24;17:209. doi: 10.1186/s13075-015-0665-7.

15.

Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent.

Verheul MK, Shiozawa K, Levarht EW, Huizinga TW, Toes RE, Trouw LA, Shiozawa S.

Rheumatology (Oxford). 2015 Oct;54(10):1930-2. doi: 10.1093/rheumatology/kev250. Epub 2015 Jul 15. No abstract available.

16.

Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study.

Janssen KM, de Smit MJ, Brouwer E, de Kok FA, Kraan J, Altenburg J, Verheul MK, Trouw LA, van Winkelhoff AJ, Vissink A, Westra J.

Arthritis Res Ther. 2015 Jul 9;17:174. doi: 10.1186/s13075-015-0690-6.

17.

Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency.

van Schaarenburg RA, Schejbel L, Truedsson L, Topaloglu R, Al-Mayouf SM, Riordan A, Simon A, Kallel-Sellami M, Arkwright PD, Åhlin A, Hagelberg S, Nielsen S, Shayesteh A, Morales A, Tam S, Genel F, Berg S, Ketel AG, Merlijn van den Berg J, Kuijpers TW, Olsson RF, Huizinga TW, Lankester AC, Trouw LA.

J Autoimmun. 2015 Aug;62:39-44. doi: 10.1016/j.jaut.2015.06.002. Epub 2015 Jun 26.

PMID:
26119135
18.

Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients.

Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, Pahau H, Lee BT, Ng J, Brunck ME, Hyde C, Trouw LA, Dudek NL, Purcell AW, O'Sullivan BJ, Connolly JE, Paul SK, Lê Cao KA, Thomas R.

Sci Transl Med. 2015 Jun 3;7(290):290ra87. doi: 10.1126/scitranslmed.aaa9301.

PMID:
26041704
19.

C1q, antibodies and anti-C1q autoantibodies.

Beurskens FJ, van Schaarenburg RA, Trouw LA.

Mol Immunol. 2015 Nov;68(1):6-13. doi: 10.1016/j.molimm.2015.05.010. Epub 2015 May 29. Review.

PMID:
26032012
20.

Biomarkers for rheumatoid and psoriatic arthritis.

Verheul MK, Fearon U, Trouw LA, Veale DJ.

Clin Immunol. 2015 Nov;161(1):2-10. doi: 10.1016/j.clim.2015.04.005. Epub 2015 Apr 28. Review.

PMID:
25934385
Items per page

Supplemental Content

Loading ...
Write to the Help Desk